Evidence map›Paper›PMID 36844602›Full record

ArticleACS omega2023

Acylpyrazoline-Based Third-Generation Selective Antichlamydial Compounds with Enhanced Potency.

Bin Lu, Qi Qiao, Elizabeth R Park, Yuxuan Wang, John A Gilleran, Matthew Pan, Daniel S Pilch, Xiang Wu, Jacques Y Roberge, Huizhou Fan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Bin LuDepartment of Parasitology, Central South University Xiangya Medical School, Changsha, Hunan 410013, China.
Qi QiaoMolecular Design and Synthesis Core, RUBRIC, Office for Research, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
Elizabeth R ParkMolecular Design and Synthesis Core, RUBRIC, Office for Research, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
Yuxuan WangDepartment of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
John A GilleranMolecular Design and Synthesis Core, RUBRIC, Office for Research, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
Matthew PanDepartment of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
Daniel S PilchDepartment of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.ORCID https://orcid.org/0000-0002-0113-0849
Xiang WuDepartment of Parasitology, Central South University Xiangya Medical School, Changsha, Hunan 410013, China.
Jacques Y RobergeMolecular Design and Synthesis Core, RUBRIC, Office for Research, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.ORCID https://orcid.org/0000-0002-7810-4139
Huizhou FanDepartment of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States.
Rutgers, The State University of New Jersey · USCentral South University · CN

Funding

GrgA:a Multifunctional Transcription Factor that Control Chlamydial Gene ExpressionR21AI140167 · NIAID · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI FAN, HUIZHOU · 2019 to 2020
$435k
Exploration of SF3 as a Chemical Probe for Chlamydial BiologyR21AI154305 · NIAID · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI FAN, HUIZHOU · 2020 to 2021
$431k
NIAID NIH HHS R21 AI140167NIAID NIH HHS R21 AI154305
6 · The paper itself

Abstract

Chlamydiae are obligate intracellular Gram-negative bacteria and widespread pathogens in humans and animals. Broad-spectrum antibiotics are currently used to treat chlamydial infections. However, broad-spectrum drugs also kill beneficial bacteria. Recently, two generations of benzal acylhydrazones have been shown to selectively inhibit chlamydiae without toxicity to human cells and lactobacilli, which are dominating, beneficial bacteria in the vagina of reproductive-age women. Here, we report the identification of two acylpyrazoline-based third-generation selective antichlamydials (SACs). With minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of 10-25 μM against

Identifiers

PMID36844602
PMCPMC9947980
OpenAlexW4319593648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.